Pfizer Korea has quickly reapplied for reimbursement of Lorviqua, its third-generation ALK anticancer drug whose reimbursement review process recently broke down at the drug pricing negotiation stage.

According to Dailypharm’s coverage, Pfizer Korea submitted an application to expand insurance reimbursement for the ALK-positive non-small-cell lung cancer (NSCLC) treatment Lorviqua (lorlatinib) to the first-line treatment on the 12th. The drug's drug pricing negotiations with the National Health Insurance Service broke down in late May.

It remains to be seen whether Lorviqua will be able to secure reimbursement in its second attempt and how quickly the discussions will move forward.